ESMO 2017 | Is there a use for capecitabine in recurrent cervical cancer?

Domenica Lorusso, MD, PhD, from the Fondazione IRCCS Instituto Nazionale Dei Tumori, Milan, Italy, discusses treatment options for recurrent cervical cancer at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. Currently, should patients continue to progress after receiving platinum based chemotherapy, there is no effective drug that can prescribed. No available drug is able to produce a response rate of more than approximately 15%. Prospective trials have been carried out assessing the efficacy of capecitabine, which has been shown to produce a response rate of approximately 35%, a very promising result.